Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease
Identifieur interne : 000076 ( France/Analysis ); précédent : 000075; suivant : 000077Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease
Auteurs : David Devos [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-05-15.
English descriptors
- KwdEn :
Abstract
The studies of duodenal infusion of a levodopa on small groups of parkinsonian patients have reported beneficial effects on motor complications. However, little is known about the patient profile and indications for duodenal levodopa infusion. The purpose of this study is to exhaustively investigate the clinical characteristics of the population and indication, efficacy and tolerability of duodenal levodopa infusion in natural care settings. Of the 102 patients treated with duodenal levodopa infusion since 2003, 91 were enrolled in a multicentre retrospective study. The mean age was 72.7 years, with average disease duration of 17 years. Patients were at advanced stage: 91% had gait disorders, 65% had visual hallucinations, and 50% were demented (MMSE: 23). Duodenal levodopa infusion was the last line of treatment for motor complications in 98% of the patients, due to failure of or contraindication for apomorphine pump and neurosurgical treatments. Long‐term treatment was observed by 73% of the population. Of these, >90% reported an improvement in motor fluctuations, quality of life, and autonomy. There were few severe adverse events. Technical problems were commonplace. Duodenal levodopa infusion seems to be an effective last‐line therapy for motor complications in Parkinson's disease. Hence, technical improvements and earlier introduction should be considered. © 2009 Movement Disorder Society.
Url:
DOI: 10.1002/mds.22450
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: 002645
- to stream Main, to step Curation: 002305
- to stream Main, to step Exploration: 000996
- to stream France, to step Extraction: 000076
Links to Exploration step
ISTEX:C5368A4642F9B7FA553ABBC164906B03A966A238Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease</title><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C5368A4642F9B7FA553ABBC164906B03A966A238</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.22450</idno><idno type="url">https://api.istex.fr/document/C5368A4642F9B7FA553ABBC164906B03A966A238/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002645</idno><idno type="wicri:Area/Main/Curation">002305</idno><idno type="wicri:Area/Main/Exploration">000996</idno><idno type="wicri:Area/France/Extraction">000076</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease</title><author><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, EA2683 IFR114 IMPRT, CHU Lille</wicri:regionArea><wicri:noRegion>CHU Lille</wicri:noRegion><wicri:noRegion>CHU Lille</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-05-15">2009-05-15</date><biblScope unit="volume">24</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="993">993</biblScope><biblScope unit="page" to="1000">1000</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C5368A4642F9B7FA553ABBC164906B03A966A238</idno><idno type="DOI">10.1002/mds.22450</idno><idno type="ArticleID">MDS22450</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Duodopa</term><term>Parkinson's disease</term><term>continuous dopaminergic stimulation</term><term>duodenal infusion</term><term>levodopa‐related motor complications</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The studies of duodenal infusion of a levodopa on small groups of parkinsonian patients have reported beneficial effects on motor complications. However, little is known about the patient profile and indications for duodenal levodopa infusion. The purpose of this study is to exhaustively investigate the clinical characteristics of the population and indication, efficacy and tolerability of duodenal levodopa infusion in natural care settings. Of the 102 patients treated with duodenal levodopa infusion since 2003, 91 were enrolled in a multicentre retrospective study. The mean age was 72.7 years, with average disease duration of 17 years. Patients were at advanced stage: 91% had gait disorders, 65% had visual hallucinations, and 50% were demented (MMSE: 23). Duodenal levodopa infusion was the last line of treatment for motor complications in 98% of the patients, due to failure of or contraindication for apomorphine pump and neurosurgical treatments. Long‐term treatment was observed by 73% of the population. Of these, >90% reported an improvement in motor fluctuations, quality of life, and autonomy. There were few severe adverse events. Technical problems were commonplace. Duodenal levodopa infusion seems to be an effective last‐line therapy for motor complications in Parkinson's disease. Hence, technical improvements and earlier introduction should be considered. © 2009 Movement Disorder Society.</div></front></TEI><affiliations><list><country><li>France</li></country></list><tree><country name="France"><noRegion><name sortKey="Devos, David" sort="Devos, David" uniqKey="Devos D" first="David" last="Devos">David Devos</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000076 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000076 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:C5368A4642F9B7FA553ABBC164906B03A966A238
|texte= Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |